Biliary Tract Pathologies & Viral Hepatitis — Clinical Compendium

Acute Cholecystitis

Cystic duct obstruction by gallstone; steady RUQ pain > 6h radiating to right scapula, fever, leukocytosis, positive Murphy sign; RUQ US initial, HIDA gold standard.

Ascending Cholangitis

Charcot triad (Fever, Jaundice, RUQ pain) + Hypotension and Altered Mental Status = Reynolds pentad; emergent biliary decompression via ERCP.

Primary Biliary Cholangitis

Autoimmune destruction of intrahepatic bile ducts in middle-aged women; pruritus, xanthelasma, antimitochondrial antibodies (AMA+), florid duct lesion; Rx: Ursodeoxycholic acid.

Primary Sclerosing Cholangitis

Intra- and extrahepatic strictures (onion-skin fibrosis, beaded appearance on MRCP); young men with Ulcerative Colitis, p-ANCA+; high risk of cholangiocarcinoma.

Gallstone Pathogenesis

Cholesterol stones (80%, radiolucent, 4 Fs); Black pigment (chronic hemolysis, calcium bilirubinate, radiopaque); Brown pigment (biliary infection/flukes).

Acalculous Cholecystitis

Gallbladder stasis and ischemia without stones in critically ill ICU, severe burns, trauma, or prolonged TPN; treat unstable patients with percutaneous cholecystostomy.

Transaminase Ratios

AST:ALT > 2:1 in alcoholic hepatitis (B₆ depletion, Mallory-Denk bodies); ALT > AST in NAFLD and viral hepatitis; > 1,000 U/L in ischemic shock liver or acetaminophen toxicity.

Hep B Window Period

HBsAg has cleared and Anti-HBs has not yet reached detectable threshold; Anti-HBc IgM is the sole positive serologic marker of recent acute HBV infection.

The Gallbladder & Biliary Disease Spectrum

Gallbladder and biliary tract pathologies are differentiated by the anatomical location of stone impaction (cystic duct vs. common bile duct), the duration of obstruction (<6 hours vs. >6 hours), and the presence of bacterial superinfection. Correlating right upper quadrant ultrasonography, HIDA cholescintigraphy, and fractionated bilirubin/alkaline phosphatase profiles directs timely cholecystectomy or endoscopic retrograde cholangiopancreatography (ERCP).

Condition	Anatomical Obstruction Site	Clinical Manifestations	Diagnostic Strategy & Treatment
Biliary Colic	Transient stone impaction at cystic duct neck	Waxing/waning postprandial RUQ pain (< 6 hours); normal labs, no fever/peritoneal signs	RUQ ultrasound shows gallstones without wall thickening; elective outpatient cholecystectomy
Acute Cholecystitis	Persistent stone impaction in cystic duct leading to chemical and bacterial inflammation	Steady, severe RUQ pain (> 6 hours), fever, leukocytosis, positive Murphy sign (inspiratory arrest on RUQ palpation)	RUQ ultrasound (thickened gallbladder wall > 4 mm, pericholecystic fluid, sonographic Murphy); HIDA scan if equivocal; cholecystectomy within 72 hours
Choledocholithiasis	Gallstone retained within the common bile duct (CBD)	RUQ pain, jaundice, dark urine, acholic stools; elevated conjugated bilirubin and alkaline phosphatase	MRCP (magnetic resonance cholangiopancreatography) or EUS; therapeutic stone extraction via ERCP
Ascending Cholangitis	CBD obstruction with ascending bacterial infection (E. coli, Klebsiella, enterococci)	Charcot's Triad: Fever + Jaundice + RUQ pain; Reynolds Pentad: + Hypotension + Altered Mental Status (Septic shock)	Medical emergency: IV hydration, broad-spectrum antibiotics (Zosyn), and emergent biliary decompression via ERCP

Calculous vs. Acalculous Cholecystitis (HIDA Scan) & Porcelain Gallbladder / Gallstone Ileus Sequelae

In Acute Calculous Cholecystitis (prolonged >6-hour impaction of a cholesterol or black/brown pigment gallstone in the neck of the gallbladder or cystic duct), stagnant intraluminal bile salts and lysolecithin trigger chemical mucosal inflammation followed by secondary enteric bacterial invasion (E. coli, Klebsiella, Enterococcus). Patients present with constant RUQ pain radiating to the right scapula/shoulder (phrenic nerve C3–C5 referred pain), fever, leukocytosis, and a positive Murphy sign (inspiratory arrest on deep RUQ palpation), while serum Bilirubin and Alkaline Phosphatase remain NORMAL because the common bile duct is unobstructed! Right Upper Quadrant Ultrasound is the initial test of choice (showing gallstones, gallbladder wall thickening >3–4 mm, pericholecystic fluid, and a sonographic Murphy sign); if ultrasound is equivocal, obtain a HIDA Scan (Technetium-99m cholescintigraphy)—the gold standard test, which is positive when the gallbladder fails to visualize within 1–4 hours due to cystic duct occlusion (treat with IV fluids, Ceftriaxone + Metronidazole, and Laparoscopic Cholecystectomy within 24–72 hours). In critically ill ICU patients (severe burns, trauma, sepsis, prolonged TPN/fasting), gallbladder stasis and ischemia cause Acute Acalculous Cholecystitis (gallbladder wall thickening/sludge WITHOUT gallstones—treated with emergent percutaneous cholecystostomy tube drainage if too unstable for surgery). Chronic cholecystitis can cause dystrophic intramural calcification (Porcelain Gallbladder → prophylactic cholecystectomy due to gallbladder adenocarcinoma risk) or erode through a cholecystoduodenal fistula into the small bowel, impacting at the narrow ileocecal valve to cause Gallstone Ileus (Rigler triad on CT/X-ray: pneumobilia [air in the biliary tree], small bowel obstruction, and an ectopic calcified gallstone in the RLQ).

Primary Biliary Cholangitis (AMA+ Middle-Aged Women) vs. Primary Sclerosing Cholangitis (p-ANCA+ UC Men)

Whenever a patient presents with chronic cholestasis (pruritus, fatigue, jaundice, xanthelasmas, and markedly elevated Alkaline Phosphatase and GGT with normal extrahepatic bile ducts on initial ultrasound), boards test the comparison between the two autoimmune cholangiopathies: (1) Primary Biliary Cholangitis (PBC) affects middle-aged women (ages 40–60, 9:1 female predominance) with concurrent autoimmune diseases (Sjögren syndrome, Hashimoto thyroiditis, CREST syndrome) and is caused by T-cell-mediated autoimmune destruction of strictly INTRAHEPATIC small interlobular bile ducts (granulomatous 'florid duct lesion' on biopsy). The diagnostic serologic hallmark is a positive Anti-Mitochondrial Antibody (AMA, >95% specific, targeting the E2 subunit of pyruvate dehydrogenase) alongside elevated serum IgM, while MRCP/ERCP of the extrahepatic biliary tree is completely normal. First-line therapy is Ursodeoxycholic Acid (Ursodiol), a hydrophilic bile acid that slows progression to cirrhosis (with obeticholic acid as second-line and cholestyramine for pruritus). (2) Primary Sclerosing Cholangitis (PSC) affects young men (ages 20–40) with Ulcerative Colitis (~85%–90% have IBD), involves BOTH intrahepatic and extrahepatic bile ducts, is negative for AMA but positive for p-ANCA, demonstrates multifocal strictures and dilations ('beading on a string') on MRCP/ERCP with 'onion-skin' concentric periductal fibrosis on biopsy, has no proven medical therapy short of liver transplantation, and carries a 10%–15% lifetime risk of cholangiocarcinoma.

Hepatitis B Serology Master Interpretation

Hepatitis B virus (HBV)—a partially double-stranded circular DNA Hepadnavirus that replicates via an RNA intermediate using reverse transcriptase—produces three distinct antigen-antibody pairs: Surface (HBsAg / Anti-HBs), Core (HBcAg [intracellular only] / Anti-HBc IgM and IgG), and Envelope (HBeAg / Anti-HBe). Systematic interpretation of this serologic panel distinguishes acute infection, the serologic window period, chronic high-infectivity carrier states, resolved natural infection, and vaccine-induced immunity.

Clinical Stage	HBsAg	Anti-HBs	Anti-HBc IgM	Anti-HBc IgG	HBeAg	Interpretation Pearl
Acute Hepatitis B	Positive	Negative	Positive	Negative	Positive	First marker to appear is HBsAg; Anti-HBc IgM signifies acute active viral replication
Window Period	Negative	Negative	Positive	Negative	Negative	HBsAg has dropped below detectable levels, but Anti-HBs has not yet risen; Anti-HBc IgM is sole marker
Chronic Infection (High replication)	Positive	Negative	Negative	Positive	Positive	HBsAg persists > 6 months; HBeAg indicates high viral infectivity and risk of transmission
Resolved Past Infection	Negative	Positive	Negative	Positive	Negative	Natural immunity: positive for both Anti-HBs (protective antibody) AND Anti-HBc IgG
Vaccination Immunity	Negative	Positive	Negative	Negative	Negative	Recombinant vaccine contains only HBsAg; patient is Anti-HBs POSITIVE alone

DNA viruses classification (HHAPPPPy), Hepadnaviridae partial dsDNA replication, and Herpesviridae/Adenoviridae/Parvoviridae — **DNA Viruses Taxonomy & Hepatitis B Hepadnavirus Replication:** Comparative virology of the seven DNA virus families (Parvovirus B19, Papilloma/Polyoma, Adenovirus, Hepadnavirus HBV with reverse transcriptase RNA intermediate, Herpesviruses, and Poxvirus). View Full Resolution

Decoding the Five Classic HBV Serologic Profiles & The Window Period (Isolated Anti-HBc IgM)

Solve any Hepatitis B serology table in 10 seconds by checking three markers in sequence: (1) HBsAg (Hepatitis B Surface Antigen): if HBsAg is POSITIVE, the patient currently has live, active HBV infection (either Acute if present <6 months with positive Anti-HBc IgM, or Chronic if HBsAg persists >6 months with Anti-HBc IgG). (2) Anti-HBs (Hepatitis B Surface Antibody): if Anti-HBs is POSITIVE, the patient is immune and cured—now check Anti-HBc IgG (Core Antibody) to determine how they became immune: if Anti-HBc IgG is NEGATIVE (ONLY Anti-HBs is positive), the patient achieved immunity via Hepatitis B Vaccination (since the recombinant vaccine contains only pure HBsAg protein and zero core antigen!); if BOTH Anti-HBs AND Anti-HBc IgG are POSITIVE, the patient recovered from a prior natural HBV infection. (3) The Serologic 'Window Period': approximately 4 to 6 months after acute infection, HBsAg is cleared from the blood before Anti-HBs rises to detectable levels, leaving BOTH HBsAg and Anti-HBs NEGATIVE; during this window period, the ONLY positive marker of acute HBV infection is Anti-HBc IgM! Finally, HBeAg (Envelope Antigen) is a secreted marker of active viral replication and high transmissibility ('e = extra-infective'); seroconversion from HBeAg+ to Anti-HBe+ indicates transition to a low-replicative state (unless a precore mutant is present with high HBV DNA despite negative HBeAg).

Extrahepatic HBV Immune-Complex Syndromes (PAN & Membranous Nephropathy), HDV Coinfection & Post-Exposure Prophylaxis

Three clinical corollaries of Hepatitis B and C are heavily tested: (1) Extrahepatic HBV Immune-Complex Syndromes: acute HBV often presents with a prodromal serum-sickness-like syndrome (arthralgias, urticarial rash, fever), and chronic HBV antigenemia drives two classic Type III immune-complex diseases: Polyarteritis Nodosa (PAN) (necrotizing medium-vessel vasculitis with fibrinoid necrosis and renal/mesenteric microaneurysms sparing the lungs; ~30% of PAN patients are HBsAg+) and Secondary Membranous Nephropathy (or MPGN). Note that unlike RNA retroviruses, HBV can integrate into the host hepatocyte genome and cause Hepatocellular Carcinoma (HCC) even in the ABSENCE of cirrhosis (screen chronic HBV carriers every 6 months with RUQ Ultrasound + serum Alpha-Fetoprotein [AFP]; treat active chronic HBV with Entecavir or Tenofovir). (2) Hepatitis D Virus (HDV) is a defective circular RNA virus that requires the HBsAg coat of HBV to assemble infectious virions: simultaneous acquisition of HBV + HDV (Coinfection) is self-limiting in >90% of adults, whereas HDV infection of a chronic HBsAg+ carrier (Superinfection) precipitates fulminant hepatic failure and rapid cirrhosis! (3) Neonatal & Needlestick Post-Exposure Prophylaxis: an infant born to an HBsAg+ mother—or an unvaccinated healthcare worker after an HBsAg+ needlestick—must receive BOTH Passive Immunoprophylaxis (Hepatitis B Immune Globulin [HBIG]) AND Active Immunization (Recombinant HBV Vaccine) administered in SEPARATE deltoid/thigh anatomical sites within 12 hours of birth/exposure!

Gallstone Pathogenesis, Calculous vs. Acalculous Cholecystitis & HIDA Protocol

Gallstone formation (cholelithiasis) develops when biliary solutes precipitate out of solution due to supersaturation, hypomotility, and mucin hypersecretion. Cholesterol stones account for 80% of calculi in Western populations and are radiolucent on plain abdominal radiographs because they contain less than 10% calcium carbonate. Conversely, pigment stones arise from excess unconjugated bilirubin in the biliary tree and are subdivided into black pigment stones (radiopaque, sterile gallbladder bile in chronic hemolytic states) and brown pigment stones (radiolucent to faintly opaque, formed inside infected intrahepatic or extrahepatic ducts). When a stone impacts persistently in the neck of the gallbladder or cystic duct, intraluminal pressure rises, phospholipase A₂ converts lecithin into cytotoxic lysolecithin, and transmural inflammation ensues, converting transient biliary colic into acute calculous cholecystitis. In critically ill patients without gallstones, severe systemic hypoperfusion and prolonged fasting trigger acute acalculous cholecystitis, which carries a markedly higher risk of gangrenous perforation.

Gallstone / Cholecystitis Type	Primary Pathophysiologic Mechanism	Key Risk Factors & Associations	Radiographic Visibility & Diagnostic Hallmark	Definitive Clinical Management
Cholesterol Stones (80%)	Supersaturation of bile with cholesterol; decreased bile acids/lecithin; hypomotility	Obesity, female (estrogen), pregnancy, Crohn ileitis, fibrates, rapid weight loss, Native American ancestry	Radiolucent on X-ray (90%); echogenic foci with posterior acoustic shadowing on RUQ US	Observation if asymptomatic; elective laparoscopic cholecystectomy if symptomatic biliary colic
Black Pigment Stones	Chronic hemolysis → excess unconjugated bilirubin precipitates with calcium in sterile gallbladder	Sickle cell anemia, hereditary spherocytosis, thalassemia, mechanical heart valves, cirrhosis	Radiopaque on plain X-ray (50–75% due to calcium carbonate/phosphate content); US shadowing	Laparoscopic cholecystectomy; often requires concomitant splenectomy during hematologic surgery
Brown Pigment Stones	Bacterial/parasitic β-glucuronidase deconjugates bilirubin in infected bile ducts	Biliary strictures, recurrent pyogenic cholangitis, Clonorchis sinensis, Ascaris lumbricoides	Radiolucent to faintly opaque; soft, muddy stones formed directly inside intra-/extrahepatic ducts	ERCP with biliary sphincterotomy and stone extraction + praziquantel/albendazole and antibiotics
Acute Calculous Cholecystitis	Impacted cystic duct stone → mucosal lysolecithin release → transmural inflammation	Prior biliary colic, fatty meal trigger; secondary infection with E. coli, Klebsiella, Enterococcus	RUQ US: wall > 4 mm, pericholecystic fluid; HIDA scan: non-visualization of gallbladder	IV fluids, IV ceftriaxone + metronidazole, early laparoscopic cholecystectomy within 72h
Acute Acalculous Cholecystitis	Gallbladder cholestasis + splanchnic hypoperfusion/ischemia without mechanical stone obstruction	ICU patients, severe burns, polytrauma, prolonged TPN, mechanical ventilation, sepsis	RUQ US or CT: distended gallbladder, thickened wall, pericholecystic fluid, sludge, no gallstones	IV broad-spectrum antibiotics + urgent percutaneous cholecystostomy tube drainage
Emphysematous Cholecystitis	Acute cholecystitis superinfected with gas-forming organisms (Clostridium perfringens, E. coli)	Elderly men with poorly controlled diabetes mellitus and peripheral vascular disease	Plain KUB/CT/US: air within the gallbladder wall or air-fluid level in lumen; RUQ crepitus	Surgical emergency: immediate broad-spectrum IV antibiotics + emergent open or laparoscopic cholecystectomy

Point-of-Care Ultrasound of Acute Calculous Cholecystitis — **Acute Cholecystitis Sonographic Plate:** Right upper quadrant ultrasound demonstrating an impacted echogenic gallstone at the gallbladder neck with posterior acoustic shadowing, anterior gallbladder wall thickening (> 4 mm), and anechoic pericholecystic fluid collection. View Full Resolution

Cholesterol vs. Black vs. Brown Pigment Gallstone Pathophysiology

Cholesterol gallstones form when hepatic cholesterol hypersecretion overwhelms the solubilizing capacity of bile salts and phosphatidylcholine (lecithin). Classic predispositions include obesity, female sex (estrogens upregulate HMG-CoA reductase), multiparity (progesterone induces gallbladder smooth muscle hypomotility), rapid weight loss, fibrates (inhibit cholesterol 7α-hydroxylase), and Crohn disease affecting the terminal ileum (impairing enterohepatic bile acid recycling). Black pigment stones consist of polymerized calcium bilirubinate precipitated by chronic extravascular hemolysis (sickle cell disease, hereditary spherocytosis, mechanical prosthetic heart valves) or alcoholic cirrhosis. Brown pigment stones form in the setting of biliary stasis and bacterial or parasitic colonization (Escherichia coli, Clonorchis sinensis, Ascaris lumbricoides), where microbial β-glucuronidase hydrolyzes conjugated bilirubin back into insoluble unconjugated bilirubin that complexes with calcium soaps.

Diagnostic Stepwise Algorithm: RUQ Ultrasound vs. Cholescintigraphy (HIDA)

Right upper quadrant (RUQ) ultrasonography is the mandatory initial diagnostic imaging test for any patient with suspected biliary colic or acute cholecystitis. Sonographic hallmarks of cholelithiasis include mobile echogenic intraluminal foci that cast prominent posterior acoustic shadows. Acute cholecystitis is established on ultrasound by gallbladder wall thickening (> 4 mm), pericholecystic fluid, gallbladder distension, and a positive sonographic Murphy sign. When clinical suspicion for acute cholecystitis remains high despite an equivocal or nondiagnostic ultrasound, hepatobiliary iminodiacetic acid (HIDA) cholescintigraphy is the gold-standard confirmatory test. Intravenous technetium-99m-labeled HIDA is selectively taken up by hepatocytes and excreted into the common bile duct; non-visualization of the gallbladder within 60 minutes (while tracer enters the duodenum) confirms cystic duct obstruction and acute cholecystitis. Morphine administration constricts the sphincter of Oddi to reduce false-positive scans in fasting patients.

Acute Calculous vs. Acalculous Cholecystitis & Surgical Triage

Patients with uncomplicated acute calculous cholecystitis require inpatient admission, NPO status, intravenous fluid resuscitation, analgesia (ketorolac or opioids), intravenous antibiotics (ceftriaxone plus metronidazole, or piperacillin-tazobactam), and early laparoscopic cholecystectomy within 72 hours of symptom onset. Uncontrolled gangrenous cholecystitis or gas-forming Clostridium perfringens infection (emphysematous cholecystitis, classically in elderly diabetic men with crepitus and intramural air) mandates emergent surgical intervention. In contrast, acute acalculous cholecystitis occurs in critically ill ICU patients following major trauma, extensive burns, sepsis, cardiopulmonary bypass, or prolonged total parenteral nutrition (TPN) due to absence of cholecystokinin (CCK)-mediated contraction and splanchnic ischemia. Because these patients are frequently hemodynamically unstable for general anesthesia, immediate bedside percutaneous transhepatic cholecystostomy tube drainage under ultrasound guidance is the life-saving intervention of choice.

Choledocholithiasis, Acute Ascending Cholangitis & Biliary Pancreatitis Management

When a gallstone migrates out of the cystic duct or forms de novo within the common bile duct (CBD), it produces choledocholithiasis. Unlike isolated cystic duct obstruction (where bilirubin and alkaline phosphatase remain normal), CBD obstruction blocks hepatic bile excretion, causing posthepatic cholestasis characterized by dark urine (conjugated bilirubinuria), acholic clay-colored stools (absence of intestinal stercobilin), pruritus, and marked elevations in conjugated (direct) bilirubin, alkaline phosphatase (ALP), and γ-glutamyltransferase (GGT). Stagnant bile behind an obstructing CBD calculus rapidly becomes colonized by ascending duodenal flora, precipitating acute ascending cholangitis. Without prompt biliary decompression, intrabiliary pressure forces bacteria and endotoxin directly into hepatic sinusoids, leading to gram-negative bacteremia and refractory septic shock.

Biliary Condition	Anatomical Lesion	Direct Bilirubin & ALP	Gold-Standard Diagnostic Modality	Definitive Therapeutic Intervention
Biliary Colic	Transient stone impaction at cystic duct neck (< 6 hours)	Normal bilirubin, normal ALP, normal WBC	Transabdominal RUQ Ultrasound (shadowing stones, normal wall)	Elective outpatient laparoscopic cholecystectomy
Choledocholithiasis	Calculus obstructing the common bile duct (CBD) lumen	Elevated direct bilirubin (> 2–4 mg/dL) and elevated ALP/GGT	MRCP or EUS (if intermediate risk); ERCP (if high risk)	ERCP with sphincterotomy and stone extraction → same-admission lap chole
Acute Ascending Cholangitis	Infected bile proximal to CBD stone or stricture (E. coli, Klebsiella)	Markedly elevated direct bilirubin, ALP, leukocytosis, lactic acidosis	Clinical diagnosis (Charcot triad / Reynolds pentad) + RUQ US/CT	IV fluids + Piperacillin-tazobactam + urgent ERCP biliary decompression
Mirizzi Syndrome	Stone impacted in Hartmann pouch/cystic duct externally compressing CHD	Elevated direct bilirubin and ALP (mimics choledocholithiasis)	MRCP or ERCP demonstrating extrinsic common hepatic duct compression	Open or careful subtotal cholecystectomy (high risk of bile duct transection)
Gallstone Ileus	Cholecystoduodenal fistula with large stone impacted at ileocecal valve	Normal or mildly elevated ALP; hypochloremic metabolic alkalosis from vomiting	Abdominal CT (Rigler triad: pneumobilia, SBO, ectopic RLQ stone)	Surgical enterolithotomy (stone removal from ileum) ± fistula takedown

Ultrasound of Cholelithiasis with Posterior Acoustic Shadowing — **Cholelithiasis Acoustic Shadowing Plate:** Transabdominal ultrasonography demonstrating hyperechoic gallstones resting on the dependent posterior gallbladder wall with clean posterior acoustic shadowing. View Full Resolution

Choledocholithiasis Risk Stratification & Imaging Pathway (RUQ US vs. MRCP vs. ERCP)

Evaluation of suspected choledocholithiasis begins with liver chemistries and transabdominal RUQ ultrasound. On ultrasound, a normal CBD diameter is ≤ 6 mm (plus 1 mm per decade over age 60, or up to 10 mm post-cholecystectomy). Patients are stratified by ASGE guidelines into high, intermediate, or low probability of a retained CBD stone. High-risk patients (visualized stone in the CBD on ultrasound, total bilirubin > 4 mg/dL plus dilated CBD > 6 mm, or clinical ascending cholangitis) proceed directly to therapeutic endoscopic retrograde cholangiopancreatography (ERCP) for sphincterotomy and basket/balloon extraction, followed by elective cholecystectomy during the same hospitalization. Intermediate-risk patients (mildly abnormal LFTs, age > 55, or gallstone pancreatitis without overt cholangitis) undergo non-invasive confirmation via magnetic resonance cholangiopancreatography (MRCP) or endoscopic ultrasound (EUS) prior to subjecting them to the procedural pancreatitis risks of ERCP.

Charcot Triad vs. Reynolds Pentad & Emergent Biliary Decompression

Acute ascending cholangitis presents classically with Charcot triad: high spiking fever with rigors, right upper quadrant pain, and jaundice. As biliary pressure exceeds secretory pressure (> 25 cm H₂O), cholangiovenous reflux triggers systemic sepsis, adding hypotension (septic shock) and altered mental status (confusion/lethargy) to form Reynolds pentad. Polymicrobial enteric gram-negative rods and anaerobes predominate: Escherichia coli (most common), Klebsiella pneumoniae, Enterococcus faecalis, and Bacteroides fragilis. Initial resuscitation requires aggressive intravenous crystalloid hydration, correction of vitamin K-dependent coagulopathy, and immediate broad-spectrum intravenous antibiotics (piperacillin-tazobactam, cefepime plus metronidazole, or meropenem). Antibiotics alone cannot sterilize an obstructed biliary tree: urgent biliary decompression via ERCP with endoscopic sphincterotomy and stent placement within 24 hours (or emergent percutaneous transhepatic cholangiography [PTC] if altered Roux-en-Y anatomy prevents endoscopic access) is mandatory for survival.

Mirizzi Syndrome, Gallstone Ileus & Biliary Pancreatitis Nuances

Two mechanical complications of chronic cholelithiasis are classic surgical board traps. Mirizzi syndrome occurs when a large gallstone impacted in the cystic duct or Hartmann pouch externally compresses the adjacent common hepatic duct, causing obstructive jaundice and recurrent cholangitis without a stone inside the CBD lumen itself. Chronic pressure necrosis can erode through the wall to create a cholecystocholedochal fistula. Gallstone ileus occurs when a large calculus (> 2.5 cm) erodes through an inflamed gallbladder wall directly into the adherent duodenum, forming a cholecystoduodenal fistula. The stone travels distally until it impacts at the narrowest point of the gastrointestinal tract—the ileocecal valve—producing a mechanical small bowel obstruction with Rigler triad on abdominal CT/X-ray: pneumobilia (air in the biliary tree), dilated small bowel loops, and an ectopic calcified gallstone in the right lower quadrant.

Autoimmune & Cholestatic Liver Diseases: PBC vs. PSC vs. Autoimmune Hepatitis

Chronic immune-mediated hepatobiliary disorders segregate along a pathophysiologic spectrum from pure intrahepatic small-duct cholestasis to large-duct sclerosing cholangiopathy and parenchymal interface hepatitis. Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC) both present with cholestatic liver chemistries (disproportionate elevation of alkaline phosphatase and GGT relative to aminotransferases), severe pruritus from bile acid and autotaxin accumulation, and hypercholesterolemia with eyelid xanthelasmas. However, their demographic profiles, serologic markers, radiographic appearances, and oncologic complications are diametric opposites on board examinations. Autoimmune Hepatitis (AIH), by contrast, targets hepatocytes directly rather than biliary epithelium, presenting with a hepatocellular injury pattern and marked hypergammaglobulinemia (elevated serum IgG).

Feature	Primary Biliary Cholangitis (PBC)	Primary Sclerosing Cholangitis (PSC)	Autoimmune Hepatitis (AIH)
Classic Demographics	Middle-aged women (40–60 yr); F:M ratio 9:1	Young men (30–45 yr); M:F ratio 2:1	Bimodal female predominance (adolescents & 40–60 yr)
Anatomical Target	Small intrahepatic interlobular bile ducts only	Medium and large intrahepatic AND extrahepatic bile ducts	Hepatocytes at the portal-parenchymal interface
Autoimmune Associations	Sjögren syndrome, Hashimoto thyroiditis, CREST scleroderma	Ulcerative Colitis (present in 75–85% of PSC patients)	Autoimmune thyroiditis, Graves disease, Type 1 diabetes, Celiac
Serologic Hallmarks	Antimitochondrial antibody (AMA+) (> 95%), ↑ IgM, anti-gp210	p-ANCA positive (65–80%), ↑ IgM; AMA negative	Type 1: Anti-smooth muscle (ASMA) + ANA; Type 2: Anti-LKM-1; ↑ IgG
Histopathology & Imaging	Biopsy: Florid duct lesion (granulomatous destruction); normal MRCP	Biopsy: Concentric 'onion-skin' periductal fibrosis; MRCP: 'Beads-on-a-string'	Biopsy: Lymphoplasmacytic interface hepatitis, plasma cell infiltrate
Malignancy & Complications	Osteoporosis, fat-soluble vitamin deficiencies (A, D, E, K), cirrhosis, HCC	Cholangiocarcinoma (10–15% risk), gallbladder CA, colorectal CA	Rapid progression to cirrhosis and hepatocellular carcinoma if untreated
First-Line Treatment	Ursodeoxycholic acid (UDCA); obeticholic acid; liver transplant	ERCP dilation/stenting of dominant strictures; liver transplant (no drug slows progression)	Prednisone + Azathioprine (check TPMT activity before starting azathioprine)

Primary Biliary Cholangitis (PBC): AMA+, Florid Duct Lesion & Ursodeoxycholic Acid

Primary Biliary Cholangitis affects middle-aged women (age 40–60, 9:1 female predominance) with coexisting autoimmune conditions such as Sjögren syndrome, Hashimoto thyroiditis, systemic sclerosis (CREST), or rheumatoid arthritis. Autoreactive T lymphocytes attack small intralobular bile duct epithelial cells, producing the pathognomonic florid duct lesion (lymphocytic and noncaseating granulomatous destruction of interlobular bile ducts) on liver biopsy. Serology is positive for antimitochondrial antibodies (AMA, targeting the E2 subunit of pyruvate dehydrogenase) in > 95% of patients, alongside elevated serum IgM. Because extrahepatic ducts are spared, MRCP and ultrasound are normal. First-line disease-modifying therapy is ursodeoxycholic acid (UDCA), a hydrophilic bile acid that slows histologic progression and delays liver transplantation; obeticholic acid (FXR agonist) is second-line, and cholestyramine treats cholestatic pruritus.

Primary Sclerosing Cholangitis (PSC): Ulcerative Colitis, Onion-Skin Fibrosis & MRCP

Primary Sclerosing Cholangitis classically afflicts young to middle-aged men (2:1 male predominance, mean age 30–45) and exhibits an overwhelming association with inflammatory bowel disease: nearly 80% of PSC patients have Ulcerative Colitis (UC). Chronic inflammation and concentric periductal fibrosis (onion-skin bile duct fibrosis on histology) obliterate both intrahepatic and extrahepatic bile ducts. Diagnosis is established non-invasively by MRCP (or ERCP), which reveals multifocal strictures alternating with pre-stenotic dilations ('beads-on-a-string' appearance). Serology shows positive perinuclear antineutrophil cytoplasmic antibodies (p-ANCA) in up to 80% and elevated serum IgM. No medical therapy halts PSC progression; dominant extrahepatic strictures are dilated via ERCP, and liver transplantation is definitive. PSC carries a 10–15% lifetime risk of cholangiocarcinoma (screened with annual MRCP and CA 19-9) plus elevated risks of gallbladder cancer and colorectal carcinoma (requiring annual surveillance colonoscopy).

Autoimmune Hepatitis (AIH): Type 1 vs. Type 2 Autoantibodies & Immunosuppression

Autoimmune Hepatitis is a T-cell-mediated assault on hepatocytes predominantly affecting young and middle-aged women. Clinical presentation ranges from asymptomatic aminotransferase elevation to acute fulminant hepatic failure. Laboratory hallmarks include markedly elevated ALT and AST, polyclonal hypergammaglobulinemia (selective IgG elevation), and specific autoantibodies: Type 1 AIH (80% of cases, adults) is defined by anti-smooth muscle antibodies (ASMA, directed against F-actin) and antinuclear antibodies (ANA); Type 2 AIH (children and young women) is defined by anti-liver-kidney microsomal type 1 (anti-LKM-1) or anti-liver cytosol type 1 (anti-LC1) antibodies. Liver biopsy is essential for diagnosis and demonstrates lymphoplasmacytic interface hepatitis (piece-meal necrosis) invading the limiting plate, emperipolesis, and hepatocyte rosettes. First-line induction therapy consists of prednisone (or budesonide in non-cirrhotics) combined with azathioprine as a steroid-sparing maintenance agent.

Hepatocellular vs. Cholestatic LFT Patterns, Viral Hepatitis (A–E) & Direct-Acting Antivirals

Systematic interpretation of liver chemistries distinguishes primary hepatocellular necrosis (predominant AST and ALT elevation) from biliary cholestasis (predominant ALP and direct bilirubin elevation) and evaluates true hepatic synthetic capacity via prothrombin time (PT/INR, reflecting Factor VII half-life of 4–6 hours) and serum albumin (half-life 20 days). Within hepatocellular disorders, the magnitude and ratio of aspartate aminotransferase (AST) to alanine aminotransferase (ALT) pinpoint the underlying etiology. Simultaneously, distinguishing the five hepatotropic viruses (Hepatitis A, B, C, D, and E) by genome architecture, transmission route, chronicity potential, and curative antiviral regimens is a foundational board competency.

Virus	Genome & Envelope	Transmission Route	Chronicity Risk	Diagnostic Gold Standard & Curative/Suppressive Therapy
Hepatitis A (HAV)	ssRNA (+), Naked Picornavirus	Fecal-oral (raw shellfish, daycares, international travel)	0% (Never chronic); smoking causes aversion	Dx: Anti-HAV IgM (acute) vs. IgG (immune/vaccinated); Rx: Supportive care
Hepatitis B (HBV)	Partially dsDNA, Enveloped Hepadnavirus	Parenteral, sexual, perinatal vertical transmission	90% in neonates; < 5% in immunocompetent adults	Dx: HBsAg, Anti-HBc IgM/IgG, HBV DNA; Rx: Entecavir or Tenofovir (TAF/TDF)
Hepatitis C (HCV)	ssRNA (+), Enveloped Flavivirus	Parenteral (IV drug use, pre-1992 blood transfusions)	75–85% chronicity (lacks 3'→5' exonuclease proofreading)	Dx: Anti-HCV Ab → HCV RNA PCR; Rx: Sofosbuvir/Velpatasvir or Glecaprevir/Pibrentasvir
Hepatitis D (HDV)	Circular ssRNA (-), Defective Delta Virus	Parenteral, sexual (requires HBsAg coat from HBV to infect)	Low in co-infection; high fulminant/cirrhosis risk in superinfection	Dx: Anti-HDV IgM/IgG + HDV RNA in HBsAg+ patient; Rx: Pegylated interferon-α / Bulevirtide
Hepatitis E (HEV)	ssRNA (+), Naked Hepevirus	Fecal-oral (waterborne epidemics, undercooked pork/wild boar)	0% (except chronic in solid-organ transplant recipients)	Dx: Anti-HEV IgM; 20–25% mortality from fulminant liver failure in pregnant women

Histopathology of Alcoholic Hepatitis Showing Mallory-Denk Bodies — **Alcoholic Steatohepatitis & Mallory-Denk Bodies Plate:** Liver biopsy demonstrating macrovesicular steatosis, hepatocyte ballooning degeneration, neutrophilic lobular inflammation, and ropy eosinophilic intracytoplasmic Mallory-Denk bodies composed of ubiquitylated cytokeratin 8/18 intermediate filaments. View Full Resolution

Aminotransferase Ratios (AST:ALT > 2:1 vs. ALT > AST vs. > 1,000 U/L) & Mallory-Denk Bodies

In most parenchymal liver diseases—including acute or chronic viral hepatitis and non-alcoholic fatty liver disease (NAFLD/MASLD)—ALT exceeds AST (AST:ALT ratio < 1) because ALT is strictly cytosolic whereas AST is both cytosolic and mitochondrial, and ALT has a longer plasma half-life. Conversely, in alcoholic hepatitis, the AST:ALT ratio is classically > 2:1 (with both values rarely exceeding 300–500 U/L) because chronic ethanol consumption depletes pyridoxal-5'-phosphate (vitamin B₆), which is required much more heavily for hepatic ALT synthesis than AST synthesis, while acetaldehyde directly damages hepatocyte mitochondria, releasing mitochondrial AST. Histologically, alcoholic hepatitis displays neutrophilic infiltration, hepatocyte ballooning, macrovesicular steatosis, and Mallory-Denk bodies (intracytoplasmic eosinophilic inclusions of damaged cytokeratin 8 and 18 intermediate filaments). Extreme transaminase elevations (AST and ALT > 1,000–10,000 U/L) narrow the differential diagnosis to three conditions: ischemic hepatitis ('shock liver' following hypotension or cardiac arrest, accompanied by massive LDH elevation), acute acetaminophen toxicity (zone 3 centrilobular necrosis mediated by NAPQI; treat with N-acetylcysteine), and acute viral or autoimmune hepatitis.

Comparative Virology of Hepatitis A, B, C, D, and E

Hepatitis A (HAV) (naked picornavirus, ssRNA) and Hepatitis E (HEV) (naked hepevirus, ssRNA) are transmitted via the fecal-oral route (contaminated shellfish/water) and cause self-limited acute hepatitis that never progresses to chronic infection in immunocompetent hosts; however, HEV in pregnant women carries a 20–25% mortality rate from fulminant hepatic failure. Hepatitis B (HBV) is an enveloped partially double-stranded circular DNA hepadnavirus that replicates via an RNA intermediate using reverse transcriptase; vertical transmission at birth results in 90% chronicity (prevented by administering HBV vaccine plus Hepatitis B Immune Globulin [HBIG] within 12 hours of birth), whereas adult exposure resolves in 95% of cases. Hepatitis C (HCV) is an enveloped flavivirus (ssRNA) lacking proofreading 3'→5' exonuclease activity, generating hypervariable envelope glycoproteins (E1/E2) that drive chronic infection in 75–85% of patients and mixed cryoglobulinemia. Hepatitis D (HDV) is a defective circular ssRNA delta agent that requires the HBsAg coat of HBV to assemble infectious virions; HDV superinfection of a chronic HBV carrier accelerates progression to cirrhosis and hepatocellular carcinoma.

Modern Antiviral Pharmacology: HBV Polymerase Inhibitors & Pan-Genotypic HCV DAAs

Chronic Hepatitis B treatment is indicated for patients with elevated HBV DNA viral load, elevated ALT, or cirrhosis to suppress viral replication and reduce hepatocellular carcinoma risk. First-line oral agents are high-barrier nucleos(t)ide reverse transcriptase inhibitors: entecavir, tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF). Note that HBV integrates covalently closed circular DNA (cccDNA) into the host hepatocyte nucleus; prior to initiating potent immunosuppressive biologics (especially rituximab or anti-TNF-α agents), all patients must be screened with HBsAg and Anti-HBc IgG to prevent lethal HBV reactivation. For Hepatitis C, confirm active viremia by ordering an HCV RNA PCR viral load after a positive screening anti-HCV antibody test. All patients with detectable HCV RNA are treated with 8–12 weeks of oral pan-genotypic direct-acting antivirals (DAAs) targeting two distinct viral proteins: sofosbuvir/velpatasvir (NS5B RNA-dependent RNA polymerase inhibitor + NS5A replication complex inhibitor) or glecaprevir/pibrentasvir (NS3/4A protease inhibitor + NS5A inhibitor), achieving a sustained virologic response (SVR12 = cure) in > 97% of patients.

COMLEX / OMM Integration NBOME High-Yield Correlate

Hepatobiliary Viscerosomatic Reflexes, Chapman Points & OMT Protocol

Sympathetic Innervation: Preganglionic sympathetic fibers innervating the liver, gallbladder, and extrahepatic biliary ducts originate exclusively from the right T5–T9 spinal cord segments (with the liver occasionally extending from T5–T9 bilaterally, right-predominant), traverse the right greater splanchnic nerve, and synapse in the celiac ganglion before coursing along the hepatic artery proper. Acute cholecystitis or biliary colic reliably produces acute paravertebral hypertonicity, boggy tissue texture changes, and Type II somatic dysfunctions at right T6–T7.
Parasympathetic & Phrenic Innervation: Parasympathetic secretomotor and motor fibers derive from the vagus nerve (CN X) (specifically the anterior vagal trunk hepatic branch), which stimulates gallbladder contraction and sphincter of Oddi relaxation. Somatic irritation of the central diaphragmatic peritoneum overlying the gallbladder dome transmits referred pain via the right phrenic nerve (C3–C5) to the ipsilateral shoulder and trapezius ridge (Boas sign) via the supraclavicular nerves.
Anterior & Posterior Chapman Reflex Points: The anterior Chapman point for the gallbladder resides in the right 6th intercostal space from the midclavicular line to the sternal border, whereas the liver anterior Chapman point extends across the right 5th and 6th intercostal spaces. The corresponding posterior Chapman reflexes lie between the transverse processes of T6 and T7 on the right (and T5–T6 for the liver).
Counterstrain & Targeted OMT Contraindications: Anterior thoracic counterstrain points for T6/T7 are treated in flexion, whereas hypertonic right T5–T9 paraspinal muscles respond to rib raising, celiac ganglion myofascial release, and thoracoabdominal diaphragm doming. Crucially, direct hepatic and splenic pump techniques are strictly contraindicated during acute cholecystitis, ascending cholangitis, hepatic abscess, or acute viral hepatitis with tender hepatomegaly due to the risk of gallbladder rupture or capsular hemorrhage.

Board Traps & Common Distractors

PSC Malignancy Surveillance Trap: Patients with Primary Sclerosing Cholangitis (PSC) carry a 10–15% lifetime risk of Cholangiocarcinoma and a 4- to 5-fold elevated risk of Colorectal Adenocarcinoma when comorbid Ulcerative Colitis is present; initiate annual colonoscopy immediately upon diagnosing PSC (do NOT wait 8 years) alongside annual MRCP/CA 19-9.
Reynolds Pentad Mortality Trap: In Acute Ascending Cholangitis presenting with Reynolds pentad (Charcot triad + hypotension + altered mental status), antibiotics and IV fluids alone carry near 100% mortality; emergent biliary drainage via ERCP with sphincterotomy (or PTC if ERCP fails) must be performed without delay.
Gallstone Ileus & Rigler Triad Trap: A mechanical small bowel obstruction in an elderly female with no prior abdominal surgeries (no adhesions) and air in the biliary tree (pneumobilia) indicates Gallstone Ileus via a cholecystoduodenal fistula, with the stone impacted at the ileocecal valve.
Porcelain Gallbladder & Adenocarcinoma Risk: Dystrophic intramural calcification of the gallbladder wall ('porcelain gallbladder' on CT or KUB) from chronic cholecystitis carries an elevated risk of Gallbladder Adenocarcinoma; prophylactic cholecystectomy is indicated.
Equivocal Ultrasound in Acute Cholecystitis: Never exclude acute cholecystitis on the basis of a negative or equivocal RUQ ultrasound if clinical suspicion remains high; proceed to a cholescintigraphy (HIDA) scan, where non-visualization of the gallbladder confirms cystic duct obstruction.
Rituximab & Latent Hepatitis B Reactivation: Anti-CD20 therapy (rituximab) or high-dose chemotherapy can trigger fulminant, fatal reactivation of resolved or chronic Hepatitis B; always screen with HBsAg and Anti-HBc IgG before starting immunosuppression and provide prophylactic Entecavir or Tenofovir.
Hepatitis E in Pregnancy: While Hepatitis A and E are typically self-limited fecal-oral infections, acute Hepatitis E infection during the third trimester of pregnancy carries a 20–25% mortality rate from fulminant hepatic failure and disseminated intravascular coagulation.

Previous Chapter • Vol 2: Clinical Ch. 27

Esophageal Dysmotility, PUD & Gastric Neoplasms

Vol 2: Clinical Ch. 29 • Next Chapter

Malabsorption, Colorectal Polyps & Colon Cancer

Table of Contents (105 Chapters) Volume 2: Organ System Clinical Pathology • Chapter 28 of 60